AQB - AquaBounty Technologies, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.01
-0.07 (-2.27%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.08
Open3.03
Bid2.92 x 1000
Ask3.35 x 1000
Day's Range2.98 - 3.08
52 Week Range2.25 - 9.99
Volume18,115
Avg. Volume87,788
Market Cap38.609M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-1.00
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire2 months ago

    AquaBounty Technologies, Inc. Results for the quarter ended March 31, 2018

    MAYNARD, Mass., May 08, 2018-- AquaBounty Technologies, Inc., a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation, ...

  • GlobeNewswire2 months ago

    AquaBounty Technologies, Inc. Announces FDA Approval of First U.S. Facility for Commercial Production of AquAdvantage Salmon

    AquaBounty Technologies, Inc. (AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (XON), today announces that it has received approval from the U.S. Food and Drug Administration (FDA) to raise AquAdvantage® Salmon at its land-based contained facility near Albany, Indiana. The FDA previously approved AquaBounty’s New Animal Drug Application (NADA) on November 19, 2015, for the production, sale, and consumption of AquAdvantage Salmon in the United States.

  • We're sorry this is all we were able to find about this topic.